CN101919866B - Method for inhibiting content decrease of Vit D2 after sterilization - Google Patents
Method for inhibiting content decrease of Vit D2 after sterilization Download PDFInfo
- Publication number
- CN101919866B CN101919866B CN2010102525881A CN201010252588A CN101919866B CN 101919866 B CN101919866 B CN 101919866B CN 2010102525881 A CN2010102525881 A CN 2010102525881A CN 201010252588 A CN201010252588 A CN 201010252588A CN 101919866 B CN101919866 B CN 101919866B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- edetate
- sterilization
- injection
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug composition of complex fat-soluble vitamins, comprising vitamin A, vitamin D2, vitamin E, vitamin K1 and a metal ion chelating agent (such as ethylenediaminotetraacetateedetate). The drug composition can be prepared into emulsion for injection, can better solve the problem that the active ingredients (vitamin D2 and vitamin K1) of the composition are oxidized in the processes of preparation and sterilization and generate degradation products, and ensures safety of clinical medication.
Description
The present invention is for dividing an application, and the original bill application number is 200710120305.6, and the original bill applying date is on August 15th, 2007, and the original bill name is called pharmaceutical composition of complex fat-soluble vitamins and preparation method thereof.
Invention field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, particularly a kind of fatsoluble vitamin class pharmaceutical composition and preparation method thereof.
Background technology
Fatsoluble vitamin is one of indispensable ingredient of parenteral nutrition, in order to satisfy the every day of being grown up to fat-soluble A, vitamin D
2, vitamin E, vitamin K
1Physiological need.According to the recipe quantity preparation fatsoluble vitamin injection that feeds intake, to fatsoluble vitamin injection vitamin A, vitamin E, vitamin D before and after sterilization
2And vitamin K
1Carry out assay, as a result vitamin D
2And vitamin K
1Content content after sterilization only be about respectively the sterilization before 47.1% and 7.7%.
The present invention is intended to solve the compound liposoluble vitamins problem that content sharply descends after sterilization.
Summary of the invention
First purpose of the present invention is to disclose a kind of pharmaceutical composition of compound liposoluble vitamins; Second purpose of the present invention is to disclose this preparation of drug combination method; The 3rd purpose of the present invention is to disclose a kind of vitamin D
2Or vitamin K
1The method of sterilization.
The present invention seeks to realize through following technical scheme:
Pharmaceutical composition of the present invention, its crude drug comprises following component:
Vitamin A 0.005-0.2 weight portion, vitamin D
20.00002-0.001 weight portion, vitamin E 0.05-2.0 weight portion, vitamin K
10.005-0.2 weight portion, metal ion chelation agent 0.025-0.2 weight portion;
Pharmaceutical composition of the present invention, its crude drug comprises following component:
With vitamin A 0.099 weight portion, vitamin D
20.0005 weight portion, vitamin E 0.91 weight portion, vitamin K
10.015 weight portion, metal ion chelation agent 0.05 weight portion;
Pharmaceutical composition of the present invention, its crude drug comprises following component:
With vitamin A 0.069 weight portion, vitamin D
20.001 weight portion, vitamin E 0.64 weight portion, vitamin K
10.02 weight portion, metal ion chelation agent 0.05 weight portion;
Metal ion chelation agent of the present invention is meant edetate; The preferred calcio-disodium edetate of above-mentioned edetate.
Compositions of the present invention can add adjuvant by common process and process clinical acceptable forms such as tablet, capsule, oral liquid granule.
The method for preparing of the emulsion medicine injection of compound liposoluble vitamins of the present invention is: get water for injection 25-250 parts by volume, ethylenediaminetetraacetic acid dicalcium sodium 0.025-0.2 weight portion and glycerol 12-50 weight portion; Mixing; Be heated to about 40～60 ℃; Add lecithin 5-20 weight portion dispersed with stirring, get solution 1; With vitamin A 0.005-0.2 weight portion, vitamin D
20.00002-0.001 weight portion, vitamin E 0.05-2.0 weight portion, vitamin K
10.005-0.2 weight portion adds in the soybean oil 80-120 weight portion, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to the 800-1200 parts by volume, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
The method for preparing of the emulsion medicine injection of compound liposoluble vitamins of the present invention is preferably: get water for injection 100 parts by volume, ethylenediaminetetraacetic acid dicalcium sodium 0.05 weight portion and glycerol 22 weight portions; Mixing; Be heated to about 40～60 ℃, add lecithin 12 weight portion dispersed with stirring, get solution 1; With vitamin A 0.099 weight portion, vitamin D
20.0005 weight portion, vitamin E 0.91 weight portion, vitamin K
10.015 weight portion adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000 parts by volume, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Another method for preparing of the emulsion medicine injection of compound liposoluble vitamins of the present invention is preferably: get water for injection 100 parts by volume, ethylenediaminetetraacetic acid dicalcium sodium 0.05 weight portion and glycerol 22 weight portions; Mixing; Be heated to about 40～60 ℃; Add lecithin 12 weight portion dispersed with stirring, get solution 1; With vitamin A 0.069 weight portion, vitamin D
20.001 weight portion, vitamin E 0.64 weight portion, vitamin K
10.02 weight portion adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000 parts by volume, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Soybean oil of the present invention can use safflower oil, Oleum Gossypii semen, Semen Maydis oil, olive oil, Semen Sesami wet goods vegetable oil to substitute.
Lecithin of the present invention can use soybean lecithin, egg yolk lecithin to substitute.
The ratio of weight portion of the present invention and parts by volume is a grams per milliliter.
The pharmaceutical composition of compound liposoluble vitamins of the present invention can be controlled vitamin D preferably
2And vitamin K
1Content content after sterilization problem that sharply descends, the use of metal ion chelation agent (edetate) is to suppressing vitamin D
2And vitamin K
1Content descends, and produces other not clear related substances to health effects; Preferably resolve its effective ingredient (vitamin D
2And vitamin K
1) structure is prone to take place the problem that the oxidation generation causes content sharply to descend in preparation and sterilization process.
Vitamin D of the present invention
2Or vitamin K
1The technical scheme of sterilizing methods be:
A kind of vitamin D
2Sterilizing methods, this method comprises: the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.02-1: 25-200.
Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.1: 30.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.2: 50.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.3: 80.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.4: 100.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.6: 50.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.7: 120.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.7: 140.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.7: 160.Vitamin D of the present invention
2Sterilizing methods, at vitamin D
2What add edetate weight in the raw material preferably is: vitamin D
2: edetate=0.8: 120.
Vitamin K of the present invention
1The technical scheme of sterilizing methods be:
A kind of vitamin K
1Sterilizing methods, this method comprises: the raw material vitamin K
1Middle adding weight ratio is a vitamin K
1: the edetate of edetate=5-200: 25-200.
Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=20: 30.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=20: 40.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=20: 50.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=30: 70.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=70: 90.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=110: 90.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=120: 90.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=130: 90.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=140: 90.Vitamin K of the present invention
1Sterilizing methods, at vitamin K
1What add edetate weight in the raw material preferably is: vitamin K
1: edetate=140: 180.
Vitamin D of the present invention
2Or vitamin K
1Sterilizing methods in the preferred calcio-disodium edetate of edetate, disodiumedetate or N-(2-the ethoxy)-diethylamine triacetic acid trisodium any one.
Pharmaceutical composition of the present invention can solve its effective ingredient (vitamin D2, vitamin K1) preferably the problem that oxidation produces catabolite takes place in preparation and sterilization process, has guaranteed safety of clinical administration.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example 1 stabilizing agent screening experiment research
With pharmaceutical composition of the present invention; Prepare respectively by embodiment 1～3 method for preparing that to contain calcio-disodium edetate content be 0.001%, 0.0025%, 0.005% compound liposoluble vitamins injection, and preparation does not add the compound liposoluble vitamins injection of calcio-disodium edetate in this way.Carry out the content detection of each fatsoluble vitamin in the compound liposoluble vitamins according to the content assaying method of determining, the result sees table 1.
Table 1 stabilizing agent screening test result
Table 1 result of the test shows: adding 0.0025%～0.02% calcio-disodium edetate as compound liposoluble vitamins injection stabilizing agent addition, all can guarantee vitamin D in the compound liposoluble vitamins injection
2And vitamin K
1Before and after sterilization, remain unchanged basically.
Above-mentioned correlation test result shows that compositions of the present invention is vitamin D before and after the compound liposoluble vitamins injection is sterilized
2And vitamin K
1There is the obvious suppression effect sharply decline aspect of content, is suppressing sterilization front and back vitamin D
2And vitamin K
1Sharply decline aspect of content obviously is superior to not adding the stabilizing agent situation, has obvious suppression sterilization front and back vitamin D
2And vitamin K
1The effect that content sharply descends.Simultaneously, the compositions of the above-mentioned form of the present invention to the sterilization before and after vitamin D
2And vitamin K
1Content sharply descends has obvious inhibitory action, thereby can reduce the waste to raw material, has reduced the patient because sterilization front and back vitamin D
2And vitamin K
1Content sharply descends and possibly produce catabolite and the various unpredicted undesirable element that produces.
The experimentation of experimental example 2 stabilizing agents screening
With pharmaceutical composition of the present invention; Respectively calcio-disodium edetate is changed to the preparation that disodiumedetate carries out the compound liposoluble vitamins injection by embodiment 1～3 method for preparing, and prepares the compound liposoluble vitamins injection that does not add disodiumedetate in this way.Carry out the content detection of each fatsoluble vitamin in the compound liposoluble vitamins according to the content assaying method of determining, the result sees table 2.
Table 2 stabilizing agent screening test result
Table 2 result of the test shows: adding 0.0025%～0.02% disodiumedetate as compound liposoluble vitamins injection stabilizing agent addition, all can guarantee vitamin D in the compound liposoluble vitamins injection
2And vitamin K
1Before and after sterilization, remain unchanged basically.
Above-mentioned correlation test result shows that compositions of the present invention is vitamin D before and after the compound liposoluble vitamins injection is sterilized
2And vitamin K
1There is the obvious suppression effect sharply decline aspect of content, is suppressing sterilization front and back vitamin D
2And vitamin K
1Sharply decline aspect of content obviously is superior to not adding the stabilizing agent situation, has obvious suppression sterilization front and back vitamin D
2And vitamin K
1The effect that content sharply descends.Simultaneously, the compositions of the above-mentioned form of the present invention to the sterilization before and after vitamin D
2And vitamin K
1Content sharply descends has obvious inhibitory action, thereby can reduce the waste to raw material, has reduced the patient because sterilization front and back vitamin D
2And vitamin K
1Content sharply descends and possibly produce catabolite and the various unpredicted undesirable element that produces.
Experiment is found: disodiumedetate can be combined into the minimizing that soluble complex causes calcium with calcium ion, uses disodiumedetate can cause blood calcium to descend in the intravenous formulations.
The experimentation of experimental example 3 stabilizing agents screening
With pharmaceutical composition of the present invention; Respectively calcio-disodium edetate being changed to diethylenetriamine pentaacetic acid preparation by embodiment 1 method for preparing, to contain diethylenetriamine pentaacetic acid content be 0.001%, 0.0025%, 0.005%, 0.01%, 0.02% compound liposoluble vitamins injection, and preparation does not add the compound liposoluble vitamins injection of diethylenetriamine pentaacetic acid in this way.Carry out the content detection of each fatsoluble vitamin in the compound liposoluble vitamins according to the content assaying method of determining, the result sees table 3.
Table 3 stabilizing agent screening test result
The experimentation of experimental example 4 stabilizing agents screening
With pharmaceutical composition of the present invention; Respectively calcio-disodium edetate being changed to diethylenetriamine pentaacetic acid trisodium preparation by embodiment 1 method for preparing, to contain diethylenetriamine pentaacetic acid three sodium contents be 0.001%, 0.0025%, 0.005%, 0.01%, 0.02% compound liposoluble vitamins injection, and preparation does not add the compound liposoluble vitamins injection of diethylenetriamine pentaacetic acid trisodium in this way.Carry out the content detection of each fatsoluble vitamin in the compound liposoluble vitamins according to the content assaying method of determining, the result sees table 4.
Table 4 stabilizing agent screening test result
The experimentation of experimental example 5 stabilizing agents screening
With pharmaceutical composition of the present invention; Respectively calcio-disodium edetate being changed to N-(2-ethoxy)-diethylamine triacetic acid trisodium preparation by embodiment 1 method for preparing, to contain N-(2-ethoxy)-diethylamine triacetic acid three sodium contents be 0.001%, 0.0025%, 0.005%, 0.01%, 0.02% compound liposoluble vitamins injection, and preparation does not add the compound liposoluble vitamins injection of N-(2-ethoxy)-diethylamine triacetic acid trisodium in this way.Carry out the content detection of each fatsoluble vitamin in the compound liposoluble vitamins according to the content assaying method of determining, the result sees table 5.
Table 5 stabilizing agent screening test result
Following embodiment all can realize the described effect of above-mentioned experimental example
The specific embodiment
Embodiment 1: the preparation of injection
Get water for injection 100ml, calcio-disodium edetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 2: the preparation of injection
Get water for injection 100ml, calcio-disodium edetate 0.025g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 3: the preparation of injection
Get water for injection 100ml, calcio-disodium edetate 0.001g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 4: the preparation of injection
Get water for injection 100ml, calcio-disodium edetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 69mg, vitamin D
21mg, vitamin E 0.64g, vitamin K
120mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 5: the preparation of injection
Get water for injection 25ml, calcio-disodium edetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 6: the preparation of injection
Get water for injection 250ml, calcio-disodium edetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 7: the preparation of injection
Get water for injection 100ml, disodiumedetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in soybean oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 8: the preparation of injection
Get water for injection 100ml, disodiumedetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds Semen sojae atricolor lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in safflower oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 9: the preparation of injection
Get water for injection 100ml, disodiumedetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds egg yolk lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in Oleum Gossypii semen 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 10: the preparation of injection
Get water for injection 100ml, disodiumedetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds Semen sojae atricolor lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in Semen Maydis oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 11: the preparation of injection
Get water for injection 100ml, disodiumedetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds Semen sojae atricolor lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 99mg, vitamin D
20.5mg, vitamin E 0.91g, vitamin K
115mg adds in olive oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 12: the preparation of injection
Get water for injection 100ml, calcio-disodium edetate 0.05g and glycerol 22g, mixing is heated to about 40～60 ℃, adds lecithin 12g dispersed with stirring, gets solution 1; With vitamin A 69mg, vitamin D
21mg, vitamin E 0.64g, vitamin K
120mg adds in Oleum sesami oil 100 weight portions, stirs, and gets solution 2; Solution 1 mixed forming colostric fluid with solution 2, add water to 1000ml, through the emulsifying of high pressure dispersing emulsification machine, adjust pH, rolls lid at filtration, fill, and sterilization promptly gets injectable emulsion.
Embodiment 13: keep vitamin D
2The method of stability during sterilization
Add sodium ethylene diamine tetracetate, adding weight is vitamin D
2: sodium ethylene diamine tetracetate=1: 100.
Result of implementation is: vitamin D
2Content after the sterilization and the preceding content basically identical of sterilization.
Embodiment 14: keep vitamin K
1The method of stability during sterilization
Add sodium ethylene diamine tetracetate, adding weight is vitamin K
1: sodium ethylene diamine tetracetate=1: 30.
Result of implementation is: vitamin K
1Content after the sterilization and the preceding content basically identical of sterilization.
Claims (12)
1. one kind is suppressed vitamin D
2The method that content descends after sterilization is characterized in that this method comprises: the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.02-1: 25-200.
2. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.1: 30.
3. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.2: 50.
4. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.3: 80.
5. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.4: 100.
6. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.6: 50.
7. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.7: 120.
8. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.7: 140.
9. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.7: 160.
10. inhibition vitamin D as claimed in claim 1
2The method that content descends after sterilization is characterized in that the raw material vitamin D
2Middle adding weight ratio is a vitamin D
2: the edetate of edetate=0.8: 120.
11. suppress vitamin D like described any one of claim 1-10
2The method that content descends after sterilization is characterized in that edetate is a calcio-disodium edetate.
12. suppress vitamin D like described any one of claim 1-10
2The method that content descends after sterilization is characterized in that edetate is a disodiumedetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102525881A CN101919866B (en) | 2007-08-15 | 2007-08-15 | Method for inhibiting content decrease of Vit D2 after sterilization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102525881A CN101919866B (en) | 2007-08-15 | 2007-08-15 | Method for inhibiting content decrease of Vit D2 after sterilization |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101203056A Division CN101129388B (en) | 2007-08-15 | 2007-08-15 | Pharmaceutical composition of compound fat-soluble vitamin and method of preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101919866A CN101919866A (en) | 2010-12-22 |
| CN101919866B true CN101919866B (en) | 2012-03-07 |
Family
ID=43335250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102525881A Active CN101919866B (en) | 2007-08-15 | 2007-08-15 | Method for inhibiting content decrease of Vit D2 after sterilization |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101919866B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843327A (en) * | 2006-04-17 | 2006-10-11 | 重庆医药工业研究院有限责任公司 | Stable freeze-dried formulation containing multiple kinds of vitamin and its preparation method |
-
2007
- 2007-08-15 CN CN2010102525881A patent/CN101919866B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843327A (en) * | 2006-04-17 | 2006-10-11 | 重庆医药工业研究院有限责任公司 | Stable freeze-dried formulation containing multiple kinds of vitamin and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 夏兆飞等."维生素D的研究进展".《中国兽医杂志》.1993,第19卷(第4期),第50-53页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101919866A (en) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101022786B (en) | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients | |
| CN101129388B (en) | Pharmaceutical composition of compound fat-soluble vitamin and method of preparing the same | |
| JPH05506458A (en) | Nutritional supplement containing vitamin E | |
| CA2765748C (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
| TWI597070B (en) | Infusion preparation | |
| KR101634015B1 (en) | Low-concentration nutritional composition | |
| CN106491520A (en) | A kind of coenzyme Q 10 injection liquid formulation and preparation method thereof | |
| JP5432563B2 (en) | Phosphatidylserine-containing capsule and phosphatidylserine composition for capsule filling | |
| KR20130089196A (en) | Composition containing stabilized coenzyme q10 at high concentration | |
| CN101919831B (en) | Method for inhibiting content decrease of Vit K1 after sterilization | |
| CN101919866B (en) | Method for inhibiting content decrease of Vit D2 after sterilization | |
| EP3383371B1 (en) | Pharmaceutical formulation | |
| JPH0741422A (en) | Method for solubilizing gamma-oryzanol in water | |
| MXPA02002174A (en) | Parenteral cisplatin emulsion. | |
| EP2435022B1 (en) | Self-microemulsifying mitotane composition | |
| KR20080106219A (en) | Stabilizer for hydrophobic compounds | |
| CA3117475A1 (en) | Oral composition containing reduced coenzyme q10, method for producing same, method for preventing discoloration and discoloration preventing agent | |
| JP3278427B2 (en) | Method for producing capsules | |
| TW202102264A (en) | Novel method for producing lecithin organogel | |
| JP4969989B2 (en) | Phospholipid composition, food composition containing the same, pharmaceutical composition, and method for producing the same | |
| KR101813987B1 (en) | Paste Composition having Omega-3 Fatty Acid and Manufacturing Method of the Same | |
| JP5091455B2 (en) | Coenzyme Q10-containing emulsion composition | |
| JP2004323404A (en) | W/o/w type multiple emulsion | |
| CN106606780A (en) | Polyene phosphatidyl choline composition, polyene phosphatidyl choline soft capsule and preparation methods | |
| JP2005112731A (en) | Hepatic function ameliorating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |